China Runji Cement (OTCBB: CRJI) Closed at $0.62. Announced today that its second cement clinker production line has successfully broken through its designed capacity of 2,500 tons per day and produced 2,700 tons per day and 2,800 tons per day in November and December 2008, respectively, to meet the growing market demand.
Meanwhile, CRJI's first cement production line, which was also designed to produce 2,500 tons per day, successfully achieved its production target of 1 million tons in 2008.
Chairman and CEO, Mr. Zhao Shouren stated. ``In response to the growing demand in our market, we are taking many initiatives to increase our production capacity. We engaged over 30 qualified, motivated and experienced technicians and workers to further strengthen our technical operation team in 2008. By increasing the capacity of our two production lines, we are able to further reduce fixed production costs and meet increasing demand among our customers. Despite the global slowdown, we expect to continue 2008's strong growth into 2009.''
What They Do: China Runji Cement, Inc. is one of the leading players in cement production and distribution. The Company's certified manufacturing facilities which contain cutting-edge technology and advanced equipment are capable of producing as much as 2 million tons of cement annually. Furthermore, the Company's solid distribution network and customer-orientated services have earned Runji's products a superior reputation among its customers.
What They Do: China Runji Cement, Inc. is one of the leading players in cement production and distribution. The Company's certified manufacturing facilities which contain cutting-edge technology and advanced equipment are capable of producing as much as 2 million tons of cement annually. Furthermore, the Company's solid distribution network and customer-orientated services have earned Runji's products a superior reputation among its customers.
How They Trade: CRJI has a 52 week high of $2.10 and a 52 week low of $0.20.
Triangle Petroleum (OTCBB: TPLM) Closed at $0.25. Today announced the following update on its 516,000 gross acre shale gas project on the Windsor Block in Nova Scotia, Canada. Completion operations on the first vertical exploration well (N-14-A) have started up again after the holiday break. Completion operations on the second vertical exploration well (O-61-C) have now been planned and should move forward pending equipment availability and partner concurrence. The Company has determined that there are five to six potential zones of interest in this well, including deep tight sand and shale, mid-depth conventional carbonate and sandstone intervals, and a potential shallow gas zone.
Technical evaluation, including shale-focused geochemical and rock evaluation of the third vertical exploration well (E-38-A) is almost complete. Completion operations should move forward once government approvals and partner concurrence have been obtained. Results from these completion operations will be reported after the Company has had the opportunity to fully evaluate the extensive suite of technical data received from the three wells.
What They Do: Triangle is an exploration company focused on an emerging Canadian shale gas project covering 516,000 gross acres in the Maritimes Basin in Nova Scotia through Elmworth Energy Corporation, its Calgary-based operating subsidiary.
How They Trade: TPLM has a 52 week high of $2.40 and a 52 week low of $0.54.
WorldWater & Solar Technologies (OTCBB: WWAT) Closed at $0.33. Today announced that it has changed its corporate name to Entech Solar, Inc., effective January 12, 2009. The Company’s ticker will remain “WWAT.OB” temporarily until the Company is reassigned a new one. ENTECH, Inc. will continue as a subsidiary of Entech Solar, Inc.
What They Do: Entech Solar is a leading provider of concentrating solar energy systems. Entech designs, manufactures and installs systems that provide both electricity and thermal energy for commercial and industrial applications.
How They Trade: WWAT has a 52 week high of $2.36 and a 52 week low of $0.31.
Genta Incorporated (OTCBB: GNTA). Today announced the presentation of a progress update on the Company’s ongoing Phase 3 trial of Genasense® (oblimersen sodium) Injection, Genta’s lead oncology product, in patients with advanced melanoma. The data were presented in conjunction with the 27th Annual JP Morgan Healthcare Conference in San Francisco, CA.
To date, more than three-quarters of the expected total number of 300 patients have been randomized into AGENDA. A total of 77 sites in 12 countries are open in Europe, the U.S., Canada, and Australia. As shown in the tables below, updated preliminary information on patient characteristics and safety findings in approximately two-thirds of patients accrued to AGENDA are similar to those in the biomarker-defined population that was accrued in the previous Phase 3 trial of Genasense, known as GM301. The incidence of serious adverse events (SAEs) in AGENDA has been somewhat lower, which may reflect the double-blind design of AGENDA compared with the open-label design of GM301.
What They Do: Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering products for the treatment of patients with cancer.
About SmallCapReview
SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/subscribe.htm. SCR is not a registered broker/dealer or financial advisor. Before making a purchase or sale of any securities featured on our website, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. SCR may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our website or within our reports. SCR has been compensated three thousand five hundred dollars by a third party Guidancemarketing for services with regards to CRJI. As with any stock, companies we select to profile involve a degree of investment risk and volatility. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies.
